Study finds over 100 value-based contracts

Despite legal barriers and practical obstacles, over 100 value-based contracts were negotiated between drug manufacturers and payers from 2014 to 2017, according to a study conducted by researchers at Duke University’s Robert J. Margolis Center for Health Policy and the National Pharmaceutical Council (NPC).

The NPC-funded study is based on online surveys completed by representatives of 12 biopharmaceutical manufacturers and 13 payers, and interviews conducted with a subset of survey respondents. ...